The consequences of percutaneous transhepatic biliary drainage (PTBD) in patients with tumoral obstructive jaundice: A retrospective study and review of literature
Executive Summary
This briefing document synthesizes findings from a large-scale retrospective study analyzing the safety and efficacy of Percutaneous Transhepatic Biliary Drainage (PTBD) in 453 patients with Malignant Obstructive Jaundice (MOJ). The study, conducted between 2017 and 2022, provides a rigorous assessment of short-term outcomes, focusing on tumor-specific complication patterns and bilirubin kinetics.
Critical Takeaways:
High Clinical Efficacy: The procedure achieved a 100% technical success rate. Mean serum bilirubin levels declined significantly within 48 hours, falling from 17.47 ± 10.61 mg/dL to 12.49 ± 8.81 mg/dL.
Superior Safety Profile: The overall complication rate was 4.6% (21 patients), which is notably lower than the 3% to 61% range reported in existing literature.
Zero Mortality: The study recorded 100% survival rates at both 30 and 90 days post-procedure; no deaths occurred from either the procedure or the underlying malignancy within the follow-up window.
Common Complications: Catheter displacement was the most frequent event (1.5%), followed by catheter bleeding (1.5%). Severe complications, such as biliary peritonitis (0.6%) and severe bleeding (0.2%), were rare and managed without surgical intervention.
Tumor-Specific Findings: While complication subtypes (non-vascular) showed some heterogeneity across tumor groups, there were no statistically significant differences in overall complication incidence between tumor types (e.g., Cholangiocarcinoma vs. Pancreatic cancer).
1. Clinical Context of Malignant Obstructive Jaundice (MOJ)
Malignant Obstructive Jaundice is a severe syndrome resulting from the mechanical blockage of bile flow. If left untreated, the condition leads to progressive hepatic dysfunction, recurrent cholangitis, and a median survival of less than 4–6 months.
Primary Etiologies
The most frequent causes of obstruction identified in the study cohort include:
Cholangiocarcinoma (CCA): 45% (204 cases)
Pancreatic Cancer: 38.4% (174 cases)
Gastric Adenocarcinoma: 5.1% (23 cases)
Peri-ampullary or Duodenal Cancer: 4.2% (19 cases)
Gallbladder Cancer: 2.4% (11 cases)
Metastatic Disease: Including colon (2.4%), lung (1.1%), esophageal (0.9%), and breast cancer (0.4%).
2. Procedural Methodology and Implementation
The study employed standardized protocols to ensure consistency and minimize risks.
Access Route: The right hepatic lobe was the preferred entry point due to larger bile ducts and favorable anatomy. The left lobe was used only when the right was not optimal.
Guidance and Catheter Selection: Procedures were performed under ultrasound and/or fluoroscopic guidance.
8 French (F) Catheters: Used for external drainage (62% of patients).
10 French (F) Catheters: Used for internal-external drainage (38% of patients).
Antibiotic Prophylaxis: All patients received intravenous ceftriaxone (1g) and metronidazole (500mg) 30–60 minutes before the procedure.
Drainage Strategy: In perihilar CCA, a single drain was initially placed in the most dilated lobe. A second contralateral drain was only added if bilirubin reduction was insufficient or cholangitis developed.
Maintenance: To prevent infection, patients were instructed not to flush catheters at home; troubleshooting was conducted only by clinical staff under sterile conditions.
3. Analysis of Clinical Outcomes
Clinical Effectiveness
The primary measure of success was the rapid restoration of biliary drainage, evidenced by early bilirubin kinetics:
Mean Absolute Reduction: 4.98 mg/dL within 48 hours.
Statistical Significance: p < 0.0001, with a moderate effect size (Cohen’s dz ≈ 0.52).
Complication Profile
A total of 22 complication events occurred in 21 patients. The study utilized patient-level attribution to avoid double-counting downstream sequelae.
4. Tumor-Specific Complication Patterns
The study uniquely stratified complications by malignancy type to identify potential variations in risk profiles.
Incidence by Group:
Cholangiocarcinoma: 2.9% complication rate.
Pancreatic Cancer: 4.6% complication rate.
Peri-ampullary/Duodenal: 15.8% (due to a smaller sample size).
Other Malignancies: 7.1%.
Statistical Findings: Despite higher absolute numbers of complications in CCA and pancreatic cancer, multivariable analysis showed that tumor type was not an independent predictor of complication risk (aOR for CCA: 0.52).
Non-Vascular Heterogeneity: Only non-vascular complications (e.g., leaks, peritonitis) showed significant heterogeneity across tumor groups (p = 0.040), suggesting that tumor biology or anatomical involvement may influence specific types of adverse events.
5. Comparative Analysis of PTBD Literature
The study's results are benchmarked against various historical and contemporary series.
Reasoning for Lower Complication Rates in Current Cohort:
Standardized technique by a single high-volume operator.
Careful access-site selection (preferring the right lobe).
Use of prophylactic antibiotics.
Avoidance of routine catheter flushing by patients.
6. Conclusions and Clinical Implications
PTBD remains an indispensable intervention for patients with malignant biliary obstruction, particularly when endoscopic approaches (ERCP) fail or are not feasible due to complex hilar anatomy.
The findings confirm that PTBD is both safe and highly effective in achieving rapid biliary decompression. While catheter displacement remains the most common minor complication, the absence of procedural mortality and the low incidence of severe vascular or infectious events (such as cholangitis) underscore the reliability of modern PTBD protocols. This study provides a robust framework for individualized risk assessment and establishes a benchmark for multidisciplinary centers managing hepato-pancreato-biliary malignancies.
